Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But ...

Minnesota Attorney General Keith Ellison says his office has settled with the last of the three largest insulin manufacturers ...

NVO Investors with Losses Encouraged to Contact the FirmSan Francisco, California--(Newsfile Corp. - January 31, 2025) - Novo Nordisk A/S (NYSE: ...

Hims & Hers, a tele-health start-up, aims to stand apart from dozens of Super Bowl commercials hawking snacks with a spot ...

Novo Nordisk A/S’s blockbuster drug Wegovy was targeted for price cuts by the US government and suffered a setback in a new ...

The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger ...

Novo Nordisk (NVO) said its popular diabetes drug Ozempic, also known as semaglutide, has been approved to reduce the risk of kidney disease worsening, kidney failure, and death from ...

The Food and Drug Administration approved Novo Nordisk's Ozempic for patients with both chronic kidney disease and diabetes, expanding the use of the wildly popular injection in the U.S. The FDA ...

Novo estimates that CKD affects some 37 million adults in the U.S., with that number likely to rise in the coming years. The condition is also a common complication of Type 2 diabetes, cropping up ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity ...